Revive Therapeutics Announces Initiation of Research Discovery Program of Cannabinoid-Based Therapies Targeting Liver Diseases

TORONTO, ONTARIO RVVTF, (Marketwired Mar 1, 2017) Revive Therapeutics Ltd. ( Revive or the Company ) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs, today announced the initiation of the research discovery program of cannabinoid-based therapeutics targeting liver diseases. The preclinical studies, including in vitro and in vitro pharmacology, will be conducted by PhytoSciences Consulting LLC, a contract research organization in Louisville, Kentucky. This novel investigation will
http://bit.ly/2mdE4EE